No Data
No Data
William Blair Initiates MiNK Therapeutics(INKT.US) With Buy Rating
MiNK Therapeutics' Earnings Call Highlights Strategic Gains
MiNK Therapeutics | 10-K: FY2024 Annual Report
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2024 Earnings Conference
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35
Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics